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myocardial infarction (AMI) has been shown to be the preferred reperfusion strategy. Adjunctive
GP IIb/IIIa inhibitors improve the outcome in patients with ST-elevation myocardial infarction
undergoing primary percutaneous intervention (PCI). Intracoronary (IC) GP IIb/IIIa bolus appli-
cation results in high local drug concentrations and may be more effective than a standard intrave-
nous bolus. It remains unclear which of the two available GP IIb/IIIa inhibitors in Egypt
eptiﬁbatide and tiroﬁban would be of great beneﬁt when used as IC bolus.
Methods: Sixty patients with anterior STEMI undergoing primary PCI in Ain Shams University
Hospitals were randomized to either intracoronary eptiﬁbatide (Integrilin) double bolus doseShams University, Faculty of
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110 T.M. Zaki et al.(n= 30) or IC tiroﬁban (Aggrastat) high bolus dose (n= 30) with subsequent 12–24 h intrave-
nous infusion of the same GP IIb/IIIa inhibitors. The primary end point was achievement of TIMI
III ﬂow and at least MBG II or III. The secondary end points were in hospital occurrence of major
adverse cardiac events (MACE) including death, recurrent ischemia and target vessel revasculariza-
tion, successful ST segment resolution and preservation of systolic function. The safety endpoint
was in hospital occurrence of any major or minor bleeding according to TIMI classiﬁcation.
Results: All baseline characteristics including demographics, risk factors, clinical data, time of
chest pain, basic ECG data and angiographic data were statistically nonsigniﬁcant among both
study groups. Regarding primary endpoint: No statistically signiﬁcant difference in achievement
of TIMI III ﬂow, but achievement of MBG II and III indicating successful perfusion was much
higher in eptiﬁbatide group (76.6%) than tiroﬁban group (36.6%) p= 0.005. Regarding secondary
end points: No statistically signiﬁcant difference in rate of in-hospital MACE among both groups
with one death (3.3%) in each group, but less recurrent ischemia in eptiﬁbatide group (0%) than
tiroﬁban group (16.7%) p= 0.026., also successful ST segment resolution as indirect sign of suc-
cessful reperfusion (70.9 ± 11.3 versus 59.7 ± 9) and systolic function preservation (EF of
46.6 ± 5.5 versus 39.9 ± 6) were signiﬁcantly better in eptiﬁbatide group p < 0.001. Regarding
safety end points: There was no difference in TIMI major bleeding among both groups but TIMI
minor bleeding had occurred in tiroﬁban group (33.3%) more than eptiﬁbatide group (0%)
p< 0.001.
Conclusion: In patient with anterior STEMI treated by primary PCI IC eptiﬁbatide was superior to
IC tiroﬁban in terms of successful perfusion, less recurrent ischemia, more ST segment resolution,
and systolic function preservation with less TIMI minor bleeding.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Primary percutaneous coronary intervention (PCI) in patients
with acute STEMI has been shown to be the preferable reper-
fusion strategy in terms of patient survival, higher rates of
patency in the infarcted arteries, and lower rates of reinfarc-
tion and stroke if performed by experienced operator and in
timely manner.1–3
Nevertheless, myocardial damage is not immediately termi-
nated after successful epicardial reperfusion because of distal
embolization of atherothrombotic material during primary
percutaneous coronary intervention (PCI) associated with
impaired myocardial perfusion, abnormal left ventricular func-
tion, and higher mortality. Current strategies are directed at
improving myocardial tissue perfusion, which is impaired in
about 50% of patients and has prognostic impact.4
Adjunctive platelet glycoprotein IIb/IIIa inhibitors enhance
the beneﬁts of primary PCI in terms of improving microcircu-
lation, tissue perfusion and hence improve outcome and reduc-
ing major adverse cardiac events (MACE). The three types of
GP IIb/IIIa inhibitors are well studied in different clinical tri-
als abciximab,5,6 eptiﬁbatide7,8 or tiroﬁban.9 Intracoronary
(IC) bolus administration of GP IIb/IIIa inhibitors with very
high local platelet inhibitor concentrations may be favorable
in dissolution of thrombi and micro emboli with subsequent
improved myocardial microcirculation and reduced no reﬂow
and infarct size with a possible decrease in systemic side
effects.10,11
Currently, clinical experience in the efﬁcacy of intracoro-
nary small molecule GP IIb/IIIa inhibitors eptiﬁbatide and
tiroﬁban administration is limited.11,12
Therefore, the aim of this study was to compare the efﬁcacy
and safety of the intracoronary bolus dose of the two available
GP IIb/IIIa inhibitors in Egypt tiroﬁban and eptiﬁbatide fol-
lowed by IV infusion as an adjunctive antiplatelet therapy inpatients with acute anterior ST segment elevation myocardial
infarction undergoing primary percutaneous intervention.
2. Methods
2.1. Patients
From June 2008 to October 2009, 60 patients with anterior
STEMI undergoing primary PCI in Ain Shams University Hos-
pitals were randomized either to receive two intracoronary
boluses of eptiﬁbatide each (180 mcg/kg) 5–10 min apart fol-
lowed immediately by continuous infusion of 2 mcg/kg/min
for 12–24 h following the primary PCI (30 patients), or to
receive high (double) intracoronary bolus dose of tiroﬁban
(25 mcg/kg) followed immediately by continuous infusion of
tiroﬁban in the dose of 0.15 mcg/kg/min for 12–24 h following
the primary PCI (30 patients). Inclusion criteria were: males
and females with age between 18 and 70 years presenting with
acute chest pain <12 h duration and new ST segment elevation
indicative of anterior myocardial infarction of at least 1 mm at
the J point in two or more contiguous leads in the anterior leads
(V1–V6, I, aVL) or new LBBB,13 and feasibility to perform PCI
within 12 h from onset of symptoms. Exclusion criteria were:
contraindications for antiplatelets such as bleeding disorder,
or any known bleeding tendency either inherited or acquired,
thrombocytopenia (platelet count <100.000/cm3), severe
uncontrolled hypertension with systolic blood pressure
persistently exceeding 200 mm Hg and/or diastolic blood pres-
sure exceeding 110 mm Hg at time of enrollment, recent
(<6 months) stroke, recent (<30 days) major surgery, severe
renal insufﬁciency (hemodialysis), previous myocardial infarc-
tion, previous revascularization either by CABG or percutane-
ous coronary intervention.
Patients presented with cardiogenic shock and patients on
mechanical ventilation.
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2.2. Study protocol
All patients were subjected to proper history taking including
presence of risk factors (smoking, hypertension, diabetes, dysl-
ipedemia and positive family history), proper analysis of chest
pain regarding onset and time and previous history of ischemia
and CCU admission. Complete physical examination with
patient classiﬁcation into four Killip classes. Serial ECG exam-
ination for magnitude of ST segment elevation and indexed ele-
vation (which account for sum of magnitude of elevated ST
segment in all leads divided by number of leads with ST eleva-
tion), andmagnitude of ST segment resolution (ST-segment res-
olution was calculated as the sum of ST elevation before minus
the sum of ST elevation after PCI divided by the sum of ST ele-
vation before PCI) ST-segment resolution was expressed as a
percentage),14 indexed resolution and time to resolution, extend
of Q wave and reperfusion arrhythmias. Full laboratory proﬁle
including serial measures of cardiac enzymes and serial follow
up of hemoglobin and platelets. Patients were prepared by
600 mg clopidogrel, 300 mg aspirin, and 70 IU/kg unfraction-
ated heparin intravenously in the catheterization laboratory.
Door to needle and door to balloon times were calculated. Cor-
onary angiography was done for each patient with non culprit
vessel angiography ﬁrst then culprit vessel angiography evaluat-
ing type of lesion, thrombus burden using thrombus scoring sys-
tem,15–17 initial TIMI ﬂow followed by primary angioplasty for
LAD in all cases of the study, the IC bolus dose of the GP IIb/
IIIa inhibitors was injected immediately after passage of thewire
or after ﬁrst balloon angioplasty aiming to achieve distal deliv-
ery of the drug to the microvascular bed in high concentration,
this was done after intracoronary injection of nitroglycerin or
verapamil at the discretion of the operator. Usage of balloons,
stents and type of the stent were decided at the discretion of
the operator. Proper post procedure angiographic assessment
was done for the occurrence of no reﬂow,18 TIMI ﬂow,19 myo-
cardial blush grade (MBG),20 TIMI frame count.21
All patients will continue on 150 mg aspirin indeﬁnitely,
75 mg clopidogrel daily and for at least 4 weeks if BMS and
for 12 months if DES, continuous heparin infusion adjusted
by PTT to be double the normal and continuous infusion of
GP IIb/IIIa inhibitors for 12–24 h after the primary interven-
tion according to the studied groups. Patients were subjected
to full echocardiographic evaluation on the third or fourth
day post infarction commenting on ejection fraction, SWMA,
LV dilatation, mechanical complication. Duration of hospital-
ization was accounted for each patient.
2.3. End points
The primary end point was achievement of TIMI III ﬂow and
at least MBG II or III. The secondary end points were in hos-
pital occurrence of major adverse cardiac events (MACE)
including death, recurrent ischemia based on clinical symptoms
and new ECG changes and target vessel revascularization, suc-
cessful ST segment resolution as an indirect parameter of myo-
cardial tissue perfusion and preservation of systolic function.
The safety endpoint was in hospital occurrence of any major
or minor bleeding according to TIMI classiﬁcation associated
with thrombocytopenia and hemoglobin drop.2.4. Statistical analysis
Continuous variables were presented as mean ± 1 SD;
categorical variables were presented as percentages. t Test
was performed for group comparison with continuous, non-
parametric, or parametric variables. Categorical variables were
compared by v2 analysis (Chi square test). Statistical signiﬁ-
cance was deﬁned as P< 0.05, highly signiﬁcant (HS) if P
value <0.01.
3. Results
Of the 60 patients enrolled, 30 patients were randomly as-
signed to IC eptiﬁbatide (Group I) and 30 patients to IC tiroﬁ-
ban (Group II). All patients received the assigned treatment
and the primary angioplasty procedure was done successfully
targeting only the culprit lesion in the infarct related artery
(left anterior descending artery).
The baseline characteristics including demographic data,
risk factors, clinical status, time of chest pain, peak cardiac en-
zymes, door to needle time and door to balloon time, ECG
data, and angiographic data were similar between the two
groups (Table 1). IC bolus administration followed by contin-
uous infusion was accomplished in all patients with no adverse
events during intracoronary bolus administration.
3.1. Post procedure angiographic analysis
The TIMI ﬂow grades before PCI were similar (Table 1). After
PCI, the majority of patients in both groups had a TIMI grade
III ﬂowwith a trend ofmore prevalent TIMI III ﬂow in eptiﬁba-
tide group (93.3% IC eptiﬁbatide versus 70% IC tiroﬁban,
P= 0.062), while the TIMI frame countwhich ismore objective
method to assess coronary ﬂow was statistically better in eptiﬁ-
batide group (p= 0.005). Myocardial blush grades (MBG) II
and III which indicate successful perfusion of the myocardium
were statistically higher in eptiﬁbatide group (76.6%eptiﬁbatide
versus 36.6% tiroﬁban, p= 0.005; Fig. 1), also no reﬂow was
signiﬁcantly less in eptiﬁbatide group (3.3% versus 26.7%,
p= 0.013) (Table 2).
3.2. Clinical outcome and MACE
All patients were followed up during their hospital stay for
development of any major adverse cardiovascular event
(MACE); there was one cardiac death (3.3%) in each group
due to severe heart failure and failed perfusion, recurrent ische-
mia in form of CP and/or ECG changes had occurred in none of
patients of eptiﬁbatide group and in ﬁve patients (16.7%) of tir-
oﬁban group (p= 0.026; Fig. 2), with no need for target vessel
revascularization in any of patients of both groups. Thus, the
composite major adverse cardiac event rate during hospital fol-
low-up was 3.3% after intracoronary eptiﬁbatide and 16.7%
after intracoronary tiroﬁban (P= 0.097).
3.3. ST-segment resolution and cardiac enzymes peaking
All indirect signs of successful reperfusion were in favor of IC
eptiﬁbatide. ST-segment resolution and resolution index were
signiﬁcantly better in the IC eptiﬁbatide than IC tiroﬁban
group (p< 0.01; Table 3). The time for maximum reperfusion
by ECG and number of leads with Q wave was also signiﬁcantly
Table 1 Baseline characteristics.
Group I IC eptiﬁbatide no. = 30 Group II IC tiroﬁban no. = 30 P value
Demographic data
Mean Age 55.46 ± 10.8 55.8 ± 10.15 >0.05 (NS)
Male sex 24 (80%) 25 (83.3%) >0.05 (NS)
Risk factors
Smoking 18 (60%) 19 (63.3%) >0.05 (NS)
FH 11 (36.7%) 11 (36.7%) >0.05 (NS)
HTN 20 (66.7%) 22 (73.3%) >0.05 (NS)
DM 17 (56.7%) 14 (46.7%) >0.05 (NS)
Dyslipidemia 11 (36.7%) 14 (46.7%) >0.05 (NS)
Clinical status, CP and cardiac enzymes
Killip class I 25 (83.3%) 24 (80%) >0.05 (NS)
Killip class II 5 (16.7%) 5 (16.7%) >0.05 (NS)
Cardiogenic shock 0 0 >0.05 (NS)
CP duration (hours) 4 ± 2.37 3.6 ± 1.3 >0.05 (NS)
DNT(min) 28.3 ± 4.4 28.8 ± 6.5 >0.05 (NS)
DBT (min) 78.16 ± 16.89 84.06 ± 13.059 >0.05 (NS)
Peak CK 4052.56 ± 1432.83 4157.86 ± 1547.10 >0.05 (NS)
Peak MB 446.53 ± 143.39 449.9 ± 180.5 >0.05 (NS)
ECG data
ST segment elevation leads 5.4 ± 1.16 5.6 ± 1.1 >0.05 (NS)
Magnitude of ST elevation 17.5 ± 4.7 19.6 ± 5.7 >0.05 (NS)
ST elevation index 3.26 ± 0.9 3.5 ± 0.95 >0.05 (NS)
Angiographic data
2 Vessel disease 5 (16.7%) 5 (16.7%) >0.05 (NS)
3 Vessel disease 4 (13.3%) 4 (13.3%) >0.05 (NS)
Lesion type
Type 2 46.6% 46.6% >0.05 (NS)
Type 3 53.3% 53.3% >0.05 (NS)
Proximal LAD lesion 20 (66.7%) 23 (76.7%) >0.05 (NS)
Mid LAD lesion 10 (33.3%) 7 (23.3%) >0.05 (NS)
Thrombus burden
Grade 1 6.6% 0% >0.05 (NS)
Grade 2 6.6% 3.3% >0.05 (NS)
Grade 3 10.3% 13.3% >0.05 (NS)
Grade 4 0% 3.3% >0.05 (NS)
Grade 5 76.6% 80% >0.05 (NS)
TIMI ﬂow before
0 27 (90%) 25 (83.3%) >0.05 (NS)
I 2 (6.6%) 4 (13.3%) >0.05 (NS)
II 1 (3.3%) 1 (3.3%) >0.05 (NS)
III 0 0 >0.05 (NS)
PTCA 22 (73.3%) 29(96.7%) >0.05 (NS)
Stenting 29 (96.7%) 28 (93.3%) >0.05 (NS)
Stent diameter 3.14 ± 0.22 2.95 ± 0.84 >0.05 (NS)
Stent length 23.27 ± 7.4 21.7 ± 7.7 >0.05 (NS)
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Figure 1 Post PCI MBG among the study groups.
112 T.M. Zaki et al.lower in eptiﬁbatide group (Table 3). Also reperfusion arrhyth-
mias were signiﬁcantly higher in eptiﬁbatide group (p< 0.01;
Table 3). Peaking of cardiac enzymes occurred signiﬁcantly ear-
lier in eptiﬁbatide group (10.2 ± 2.48 versus 14.13 ± 4.03,
p= 0.000).
3.4. Systolic function preservation
Myocardial function was assessed by transthoracic echocardi-
ography on the day 3 or 4 post infarction. Ejection fraction
was signiﬁcantly higher in eptiﬁbatide group (46.6 ± 5.49 ver-
sus 39.9 ± 6, p= 0.000; Fig. 3), preservation of LV dimen-
sions; volumes and segmental wall motion abnormality tend
to be better in eptiﬁbatide group but not statistically signiﬁcant
(p> 0.05). Mild mitral regurgitation occurred equally in both
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Figure 2 Distribution of recurrent ischemia among the study
groups.
36
38
40
42
44
46
48
GI GII
p=0.000
Mean EF
Figure 3 Mean EF of the patients of the study groups.
Table 2 Post procedure angiographic data.
Group I IC
eptiﬁbatide
no. = 30
Group II IC
tiroﬁban
no. = 30
P value
TIMI ﬂow after
0 0 0 P= 0.62
I 1 (3.3%) 3(10%)
II 1 (3.3%) 6 (20%)
III 28 (93.3%) 21 (70%)
MBG after
0 3(10%) 12(40%) P= 0.005
I 4(13.3%) 7(23.3%)
II 10 (33.3%) 8(26.6%)
III 13 (43.3%) 3 (10%)
TIMI frame count 21.233 ± 5.425 25.89 ± 06.715 P= 0.005
No reﬂow 1 (3.3%) 8 (26.7) P= 0.13
Table 3 ECG signs of reperfusion.
Group I IC
eptiﬁbatide
no. = 30
Group II
IC tiroﬁban
no. = 30
P value
Magnitude of
resolution (%)
70.967 ± 11.318 59.75 ± 9 (0.000)
<0.01 (HS)
Resolution
index (%)
57.7 ± 11.4 48.8 ± 9.45 (0.002)
<0.01 (HS)
Time for maximum
resolution (hour)
1 ± 0.347 1.46 ± 0.629 (0.001)
<0.01 (HS)
Number of leads
with Q wave
3.167 ± 0.791 3.767 ± 1 (0.013)
<0.05 (S)
Reperfusion
arrhythmias
13 (43.3%) 3 (10%) (0.004)
<0.01 (HS)
Table 4 Hemoglobin and platelet changes.
Group I IC
eptiﬁbatide
no. = 30
Group II IC
tiroﬁban
no. = 30
P value
Hemoglobin
decrease by gm/dl
1.283 ± 1.048 2.767 ± 1.4 (0.000)
<0.01 (HS)
Time to change
(days)
1.833 ± 1.48 2.433 ± 1.431 >0.05 (NS)
Platelet change
by percentage
0 25.533 ± 13.258 (0.000)
<0.01 (HS)
Time to change (days) 0 2.533 ± 0.973 (0.000)
<0.01 (HS)
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mechanical complication, and only one patient in tiroﬁban
group had LV thrombus.
3.5. Safety endpoints
No signiﬁcant difference in the TIMI major bleeding between
the two groups, only two patients in tiroﬁban group had major
bleeding complication, one of them had intracranial hemor-
rhage and the other one had severe hematemesis, both patients
were managed conservatively, no major bleeding was reported
in eptiﬁbatide group (pP 0.05).TIMI minor bleeding and puncture side bleeding were sig-
niﬁcantly higher in tiroﬁban group (33.3% minor bleeding and
43.3% puncture site bleeding in tiroﬁban group versus 0%
minor bleeding and 6.7% puncture site bleeding in eptiﬁbatide
group, p< 0.01).
Also tiroﬁban group showed signiﬁcant more hemoglobin
drop and mild thrombocytopenia (25% decreased platelet
count) occurred between second and third day than eptiﬁba-
tide group; (Table 4).
4. Discussion
With the development of reperfusion strategies and ancillary
therapies over the past three decades, the prognosis of ST eleva-
tion myocardial infarction (STEMI) has improved signiﬁcantly
with reduction in the percentage of in-hospital mortality among
patients with STEMI.22
Reperfusion of the infarct-related artery (IRA) is the cor-
nerstone of therapy for STEMI. Fibrinolysis and percutaneous
coronary intervention (PCI) are both well established as effec-
tive options, but PCI has generally come to be regarded as the
treatment of choice.1,2
The administration of glycoprotein IIb/IIIa inhibitors is
considered to provide additional beneﬁt to mechanical reperfu-
sion in the treatment of patients with ST elevation myocardial
infarction and is included as a class-IIa recommendation in the
Guidelines for Percutaneous Coronary Intervention of the
European Society of Cardiology.23 In ACC/AHA 2009 STE-
MI/PCI Guidelines Focused Update the use of GP IIb/IIIa
in PCI was addressed as class IIa level of evidence A for abcix-
imab, level of evidence B for tiroﬁban and eptiﬁbatide.24 GP
IIb/IIIa inhibitors prevent distal embolization and have been
shown to reduce ischaemic events, death, and MI in acute cor-
114 T.M. Zaki et al.onary syndromes without increasing the risk of intracranial or
severe haemorrhage.25 A relatively simple adjunctive strategy
that may have therapeutic potential during PCI in thrombotic
lesions is IC delivery of antithrombotic drugs. There is increas-
ing evidence to suggest that local delivery of GP IIb/IIIa recep-
tor antagonists directly into the coronary circulation during
PCI in patients with STEMI may improve microvascular func-
tion and clinical outcomes. The rationale for this approach is
the ability to achieve a very high concentration of the drugs
at the site of the thrombus without signiﬁcantly increasing
the risk of bleeding.26 The drug concentration after IC admin-
istration depends on coronary blood ﬂow. It has been esti-
mated that the concentration may be as much as 280-fold
greater when compared to IV delivery, depending on inﬂow
and washout of blood,10 Thus, a high concentration of anti-
thrombotic agents at the site of a thrombotic lesion may facil-
itate the diffusion of the drug into the acute thrombus, with the
potential of promoting clot dissolution in the epicardial and
microvessels. Moreover, a high local concentration leads to in-
creased receptor occupancy in the case of GP IIb/IIIa inhibi-
tors.27 IC drug delivery has the potential to increase efﬁcacy
without a greater risk of bleeding. Thus, the ability to deliver
a high drug concentration locally while maintaining a low sys-
temic level is an attractive strategy.28 In comparison to moder-
ate evidence support the use of IC abciximab regarding
efﬁcacy and safety.10,29 There are very little published data
on IC use of the small-molecule GP IIb/IIIa inhibitors in pri-
mary PCI for STEMI.
So the current study was conducted to examine the angio-
graphic, ECG, clinical outcomes and safety proﬁle in patients
with anterior ST-segment elevation AMI (STEMI) undergoing
primary PCI using IC regimen of the two available GP IIb/IIIa
inhibitors in Egypt (eptiﬁbatide in comparison to Tiroﬁban)
using initial IC double bolus dose followed by 12–24 h infusion
of the same GP IIb/IIIa inhibitors. Baseline characteristics
were similar in the two groups, post procedural TIMI III ﬂow
was more prevalent in eptiﬁbatide group in comparison to the
tiroﬁban group but this was statistically non-signiﬁcant mostly
due to low number of patients in both groups but MBG II and
III which indicate more successful reperfusion and reﬂect
much better clinical outcome and more myocardial salvage
were signiﬁcantly higher in the eptiﬁbatide group. Moreover
successful ST segment resolution with early peaking of
enzymes as indirect signs of reperfusion and more systolic
function preservation with better ejection fraction were all sig-
niﬁcantly higher in the eptiﬁbatide group. No difference in rate
of MACE among the two groups but recurrent ischemia was
signiﬁcantly higher in tiroﬁban group. It was clear that IC
eptiﬁbatide in the current study was associated with less bleed-
ing complication than tiroﬁban as regards TIMI minor bleed-
ing and puncture site bleeding but no difference as regards
TIMI major bleeding, also tiroﬁban was associated with signif-
icant mild drop in both hemoglobin and platelet count.
No similar study directly compared IC forms of eptiﬁbatide
and tiroﬁban in prospective manner, only one retrospective
study on 30 patients done by Chakraborty et al. which Com-
pared the IC form of the three GP IIb/IIIa inhibitors tiroﬁban,
abciximab and eptiﬁbatide in patients with acute coronary syn-
drome and revealed similar protection rates against MACE.30
Chakraborty et al. (2006).
There is moderate evidence support the use of IC abciximab
over IV form, the study done by Wohrle et al., showed that inpatients with acute myocardial infarction or unstable angina
(403 patients) undergoing emergency coronary angioplasty,
intracoronary bolus application of abciximab is associated with
a reduction of MACE compared with the standard intravenous
bolus application of abciximab.10 Also in the study done Thiele
et al. showed that intracoronary bolus administration of abcix-
imab is superior to standard intravenous treatment with respect
to reduction in infarct size, extent of microvascular obstruction,
and improvement of perfusion in primary PCI.29
Only little published data on the IC usage of the small mol-
ecule GP IIb/IIIa inhibitors. Pinto et al. showed that Intracor-
onary eptiﬁbatide can be administered safely during primary
PCI in patient with STEMI (59 patients) and is associated with
few adverse events. Relatively high rates of normal myocardial
perfusion were observed after primary PCI with adjunctive
intracoronary eptiﬁbatide.11
Yang et al. showed that intracoronary bolus application of
tiroﬁban was associated with superior clinical prognosis com-
pared with the standard intravenous bolus application of tir-
oﬁban in patients with STEMI (60 patients) undergoing
primary PCI.12
A lot of trials compared each of eptiﬁbatide and tiroﬁban
(especially high dose) with abciximab and showed similar efﬁ-
cacy and may be better safety especially for eptiﬁbatide.
In EVA – AMI trial done by Zeymer which compared eptif-
ibatide and abciximab in primary PCI the post procedure TIMI
III ﬂow was 84.3% for abciximab and 82.4% for eptiﬁbatide.31
In the large registry conducted by Hitinder et al. on the
Relative Safety and Efﬁcacy of Abciximab and Eptiﬁbatide
in Patients Undergoing Primary Percutaneous Coronary Inter-
vention there was no signiﬁcant difference in MACE between
patients treated by abciximab and eptiﬁbatide but the gastro-
intestinal bleeding was signiﬁcantly higher in abciximab group
while the puncture site complication and need for blood trans-
fusion were similar.32 In the study done by Gunasekara and his
colleagues the high bolus dose tiroﬁban was as effective as
abciximab in reducing the MACE but there was a small
increase in bleeding requiring transfusion in the high dose tir-
oﬁban group.33
5. Conclusion
In patient with anterior STEMI treated by primary PCI IC eptif-
ibatide was superior to IC tiroﬁban in terms of successful perfu-
sion, less recurrent ischemia, more ST segment resolution, and
systolic function preservation with less TIMI minor bleeding.
Further large prospective randomized studies are warranted to
compare IC and IV forms of each of eptiﬁbatide and tiroﬁban
and in different forms of ACS with long term follow up.References
1. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E,
et al. Comparison of primary coronary angioplasty and intrave-
nous thrombolytic therapy for acute myocardial infarction: a
quantitative review. JAMA 1998;278:2093–8.
2. Zijlstra F, Hoorntje JCA, de Boer M-J, Reiffers S, Miedema K,
Ottervanger JP, et al. Long-term beneﬁt of primary angioplasty as
compared with thrombolytic therapy for acute myocardial infarc-
tion. N Engl J Med 1999;341:1413–9.
3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA
guidelines for the management of patients with ST-elevation
Comparison between the effect of intracoronary bolus of tiroﬁban versus eptiﬁbatide as adjunctive 115myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee to Revise the 1999 Guidelines for the
Management of Patients with Acute Myocardial Infarction).
Circulation 2004;110:e82–e292.
4. Lerman A, Holmes DR, Herrmann J, et al. Microcirculatory
dysfunction in ST-elevation myocardial infarction: cause, conse-
quence, or both? Eur Heart J 2007;28:788–97.
5. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S,
Villain P, et al. For the ADMIRAL Investigators. Abciximab
before Direct angioplasty and Stenting in Myocardial Infarction
Regarding Acute and Long-Term Follow-up: Platelet glycoprotein
IIb/IIIa inhibition with coronary stenting for acute myocardial
infarction. N Engl J Med 2001;344:1895–903.
6. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A,
Vigo F, et al. A randomized trial comparing primary infarct
artery stenting with or without abciximab in acute myocardial
infarction. J Am Coll Cardiol 2003;42:1879–85.
7. The IMPACT-II Investigators. Randomised placebo-controlled
trial of effect of eptiﬁbatide on complications of percutaneous
coronary intervention: IMPACT-II. Lancet 1997; 349: 1422–28.
8. The ESPRIT Investigators. Novel dosing regimen of eptiﬁbatide in
planned coronary stent implantation (ESPRIT): A randomized,
placebo-controlled trial. Lancet 2000; 356: 2037–44.
9. Batchelor WB, Tolleson TR, Huang Y, Huang Y, Larsen R,
Mantell RM, et al. Randomized comparison of platelet inhibition
with abciximab, tiroﬁban and eptiﬁbatide during percutaneous
coronary intervention in acute coronary syndromes: The COM-
PARE trial (Clinical Investigation and Reports). Circulation
2002;106:1470–6.
10. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse
cardiac events with intracoronary compared with intravenous
bolus application of abciximab in patients with acute myocardial
infarction or unstable angina undergoing coronary angioplasty.
Circulation 2003;107:1840–3.
11. Pinto DS, Kirtane AJ, Ruocco NA, Deibele AJ, et al., Administra-
tion of intracoronary eptiﬁbatide during ST-elevation myocardial
infarction. Am J Cardiol. 2005;96(11):1494–7. [Epub 2005 Oct 17].
12. Yang XC, Zhang DP, Wang LF, Xu L, et al. Effects of
intracoronary or intravenous tiroﬁban administration in patients
with acute ST-elevation myocardial infarction undergoing primary
percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing
Za Zhi 2007;35(6):517–22.
13. Alpert JS, Thygesen K, Antman E. Myocardial infarction rede-
ﬁned a consensus document of the Joint European Society of
Cardiology/American College of Cardiology Committee for the
redeﬁnition of myocardial infarction. J Am Coll Cardiol
2000;36:959–69.
14. Schroeder R. Prognostic impact of early ST-segment resolution in
acute ST-elevation myocardial infarction. Circulation 2004;110:
e506–10.
15. Gurbel PA, Navetta FI, Bates ER, et al. Lesion-directed admin-
istration of alteplase with intracoronary heparin in patients with
unstable angina and coronary thrombus undergoing angioplasty.
Cathet Cardiovasc Diagn 1996;37:382–91.
16. Xue-Qiao Zhao, Pierre The´roux, Steven M. Snapinn, Frederic L.
Sax, for the PRISM-PLUS Investigators, intracoronary Thrombus
and Platelet Glycoprotein IIb/IIIa Receptor Blockade With
Tiroﬁban in Unstable Angina or Non–Q-Wave Myocardial
Infarction Angiographic Results From the PRISM-PLUS Trial
(Platelet Receptor Inhibition for Ischemic Syndrome Management
in Patients Limited by Unstable Signs and Symptoms) Circulation
1999;100:1609–15.
17. C. Michael Gibson, James A. Delemos, Sabina A. Murphy, Susan
J. Marble, Carolyn H. McCabe, et al., Combination Therapy With
Abciximab Reduces Angiographically Evident Thrombus in Acute
Myocardial Infarction A TIMI 14 Substudy, Circulation 2001;103;
2550–4.18. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment
of ‘‘no-reﬂow’’ after percutaneous coronary intervention. Circula-
tion 1994;89:2514–8.
19. The TIMI Study Group: Thrombolysis in myocardial infarction
(TIMI) trial. N Engl J Med 1985;312:932–6.
20. Van’t Hof AWJ, Liem A, Suryapranata H, et al. On behalf of the
Zwolle Myocardial Infarction Study Group: Angiographic assess-
ment of myocardial reperfusion in patients treated with primary
angioplasty for acute myocardial infarction: Myocardial blush
grade. Circulation 1998;97:2302–6.
21. Mark A Appleby, Andrew D Michaels, Michael Chen, et al.,
Importance of the TIMI frame count: implications for future
trials. Curr Control Trials Cardiovasc Med. 2000; 1(1): 31–34.
22. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and
adjunctive therapy in acute myocardial infarction: the Seventh
ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest 2004;126:549S–75S.
23. Silber S, Albertsson P, Avile´s FF, et al. Guidelines for percuta-
neous coronary interventions: the task force for percutaneous
coronary interventions of the European Society of Cardiology.
Eur Heart J 2005;26:804–47.
24. Kushner FrederickG, Hand Mary, Smith Sidney C. Focused
updates: ACC/AHA guidelines for the management of patients
with ST-elevation myocardial infarction (Updating the 2004
Guideline and 2007 Focused Update) and ACC/AHA/SCAI
guidelines on percutaneous coronary intervention (Updating the
2005 Guideline and 2007 Focused Update). A report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol
2009;54:2205–41.
25. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet
glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a
meta-analysis of all major randomised clinical trials. Lancet
2002;359:189–98.
26. Manivannan S, Abhiram P. Adjunctive intracoronary antithrom-
botic therapy: time to revisit an old strategy. J Invasive Cardiol
2009;21(5):224–8.
27. Gibson CM, Jennings LK, Murphy SA, et al. Association
between platelet receptor occupancy after eptiﬁbatide (integrilin)
therapy and patency, myocardial perfusion, and ST-segment
resolution among patients with ST-segment-elevation myocardial
infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute
Myocardial Infarction) substudy. Circulation 2004;110:679–84.
28. Gunn J, Cumberland DC. Has stenting killed local drug delivery?
Eur Heart J 1998;19:689–92.
29. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary
compared with intravenous bolus abciximab application in
patients with ST-elevation myocardial infarction undergoing
primary percutaneous coronary intervention: The randomized
Leipzig immediate percutaneous coronary intervention abciximab
IV versus IC in ST-elevation myocardial infarction trial. Circula-
tion 2008;118:49–57.
30. Chakraborty R, Yogendra S, Aftab K, et al. Intracoronary
glycoprotein IIb/IIIa inhibitors in acute coronary syndrome. J
Indian Med Assoc 2006;104(5):232-4–6-7.
31. UweZeymer, EVA-AMI: Eptiﬁbatide equal to abciximab for
STEMI patients undergoing PCI, American Heart Association
2007 Scientiﬁc Sessions; November 4, 2007.
32. Hitinder S, Gurm, Dean E, Smith J, Stewart C, et al. The relative
safety and efﬁcacy of abciximab and eptiﬁbatide in patients
undergoing primary percutaneous coronary intervention: insights
from a large regional registry of contemporary percutaneous
coronary intervention. J Am Coll Cardiol 2008;51(5):529–35.
33. Gunasekara AP, Walters DL, Aroney CN. Comparison of
abciximab with ‘‘high-dose’’ tiroﬁban in patients undergoing
percutaneous coronary intervention. Int J Cardiol 2006;109(1):
16–20.
